UY25101A1 - Método para el tratamiento de la diabetes mellitus y las condiciones asociadas - Google Patents

Método para el tratamiento de la diabetes mellitus y las condiciones asociadas

Info

Publication number
UY25101A1
UY25101A1 UY25101A UY25101A UY25101A1 UY 25101 A1 UY25101 A1 UY 25101A1 UY 25101 A UY25101 A UY 25101A UY 25101 A UY25101 A UY 25101A UY 25101 A1 UY25101 A1 UY 25101A1
Authority
UY
Uruguay
Prior art keywords
diabetes mellitus
insulin
mammal
alpha
treatment
Prior art date
Application number
UY25101A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Smith
Robin Buckingham
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of UY25101A1 publication Critical patent/UY25101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
UY25101A 1997-07-18 1998-07-17 Método para el tratamiento de la diabetes mellitus y las condiciones asociadas UY25101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
UY25101A1 true UY25101A1 (es) 2000-12-29

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25101A UY25101A1 (es) 1997-07-18 1998-07-17 Método para el tratamiento de la diabetes mellitus y las condiciones asociadas

Country Status (27)

Country Link
EP (1) EP1001784A1 (hu)
JP (1) JP2001510160A (hu)
KR (1) KR20010021952A (hu)
CN (1) CN1263467A (hu)
AP (1) AP2000001735A0 (hu)
AR (2) AR016350A1 (hu)
AU (1) AU8449098A (hu)
BG (1) BG104062A (hu)
BR (1) BR9810292A (hu)
CA (1) CA2297133A1 (hu)
CO (1) CO4940489A1 (hu)
DZ (1) DZ2563A1 (hu)
EA (1) EA200000140A1 (hu)
GB (1) GB9715298D0 (hu)
HU (1) HUP0003626A3 (hu)
ID (1) ID23804A (hu)
IL (1) IL133907A0 (hu)
MA (1) MA24608A1 (hu)
NO (1) NO20000230D0 (hu)
OA (1) OA11312A (hu)
PE (1) PE99499A1 (hu)
PL (1) PL338140A1 (hu)
SK (1) SK612000A3 (hu)
TR (1) TR200000133T2 (hu)
UY (1) UY25101A1 (hu)
WO (1) WO1999003478A1 (hu)
ZA (1) ZA986364B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO2000078333A2 (en) 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
BRPI0107715B8 (pt) * 2000-01-21 2021-05-25 Novartis Ag produto farmacêutico compreendendo um inibidor de dipeptidilpeptidase-iv e metformina, bem como usos do dito produto farmacêutico e do inibidor de dipeptidilpeptidase-iv
WO2001062295A1 (fr) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Medicaments contenant des ingredients actifs combines
JP4917712B2 (ja) * 2000-02-24 2012-04-18 武田薬品工業株式会社 併用医薬
WO2002055009A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
NZ546337A (en) 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
CN101103993B (zh) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 降糖药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
PE99499A1 (es) 1999-12-18
MA24608A1 (fr) 1999-04-01
AU8449098A (en) 1999-02-10
JP2001510160A (ja) 2001-07-31
BG104062A (en) 2000-11-30
ZA986364B (en) 2000-01-17
WO1999003478A1 (en) 1999-01-28
DZ2563A1 (fr) 2003-02-15
CA2297133A1 (en) 1999-01-28
EA200000140A1 (ru) 2000-06-26
AR019724A2 (es) 2002-03-13
ID23804A (id) 2000-05-11
OA11312A (en) 2003-10-24
PL338140A1 (en) 2000-09-25
NO20000230L (no) 2000-01-17
AR016350A1 (es) 2001-07-04
CN1263467A (zh) 2000-08-16
HUP0003626A3 (en) 2001-12-28
BR9810292A (pt) 2000-09-19
KR20010021952A (ko) 2001-03-15
NO20000230D0 (no) 2000-01-17
SK612000A3 (en) 2000-07-11
IL133907A0 (en) 2001-04-30
GB9715298D0 (en) 1997-09-24
EP1001784A1 (en) 2000-05-24
TR200000133T2 (tr) 2000-09-21
HUP0003626A2 (hu) 2001-05-28
AP2000001735A0 (en) 2000-01-16
CO4940489A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
AR057970A2 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
UY25101A1 (es) Método para el tratamiento de la diabetes mellitus y las condiciones asociadas
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
PE99599A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
UY24893A1 (es) Combinaciones para diabetes de sulfonilurea glitazona
NO20083276L (no) Behandling av diabetes med tiazolidindion og sulfonylurea
AR012997A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.
AR045230A1 (es) Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2- piridil)-amino)-etoxi]-bencil]-tiazolidino-2,4-diona y otro agente antidiabetico adicional; procedimiento para su preparacion y uso de 5-[4-[2-(metil-n-(2-piridil)-amino)-etoxi]- bencil]- tiazolidino-2,4-diona y otro agente antidiabetic
PE89199A1 (es) Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes
AR016768A1 (es) COMPOSICIoN FARMACÉUTICA DE 5-(4- (2-(N-METIL-N-(2-PIRIDIL) AMINO)ETOXI)BENCIL)TIAZOLIDIN-2-4-DIONA Y UN SECRETAGOGO DE INSULINA Y USO DE LA MISMA PARA PREPARACIoN DE MEDICAMENTOS
UY26112A1 (es) Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
AR104503A2 (es) Compuestos heterocíclicos de ácido borónico
NO20075507L (no) Tiazolidindionderivater og deres anvendelse som antidiabetiske midler
BR0111536A (pt) Sal de tiazolidinediona para tratamento de diabetes mellitus
DK1315724T3 (da) Thiazolidindionderivat og dets anvendelse som antidiabetikum
RU2021105658A (ru) Способы отсрочки возникновения диабета 2 типа и замедления прогрессии, и лечения диабета 2 типа
ECSP982535A (es) Nuevo metodo de tratamiento (i)
ECSP982541A (es) Nuevo metodo de tratamiento ii
HUP0003673A2 (hu) Dioxo-tiazolidinek alkalmazása a hyperglykaemia kezelésére
TH36757A (th) กรรมวิธีในการรักษาเบาหวานด้วยไธอะโซลิดีนไดโอนและซัลโฟนิลยูเรีย
ECSP982593A (es) Nuevo metodo de tratamiento vi

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20121207